Supernus Pharmaceuticals (SUPN) Net Cash Flow (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Net Cash Flow data on file, last reported at $56.4 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 21.29% year-over-year to $56.4 million in Q1 2026; TTM through Mar 2026 was $70.5 million, a 34.37% increase from a year earlier, with the FY2025 full-year figure at $60.6 million, up 1158.31% from the prior year.
• Net Cash Flow for Q1 2026 stood at $56.4 million, up from -$22.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for SUPN reached as high as $369.1 million in Q1 2023 and fell as low as -$437.5 million in Q2 2023.
• Historically, Net Cash Flow has averaged -$1.0 million across 5 years, with a median of -$11.3 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 520.75% in 2023 and fell as far as 858.05% in 2023.
• Year by year, Net Cash Flow stood at -$18.4 million in 2022, then retreated by 8.49% to -$19.9 million in 2023, then surged by 288.94% to $37.7 million in 2024, then tumbled by 160.87% to -$22.9 million in 2025, then surged by 346.13% to $56.4 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $56.4 million in Q1 2026, -$22.9 million in Q4 2025, and $8.1 million in Q3 2025.